HF
SPRY icon

HRT Financial’s ARS Pharmaceuticals SPRY Stock Holding History

HRT Financial’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-68,645
Closed -$799K – 4669
2025
Q4 		$799K Buy
+68,645
New +$668K ﹤0.01% 1857
2025
Q2 		– Sell
-23,845
Closed -$299K – 3467
2025
Q1 		$299K Buy
+23,845
New +$287K ﹤0.01% 1780
2023
Q2 		– Sell
-135,684
Closed -$883K – 3230
2023
Q1 		$883K Buy
+135,684
New +$1.04M 0.01% 1011
2022
Q1 		– Sell
-63,588
Closed -$423K – 3814
2021
Q4 		$423K Buy
63,588
+37,554
+144% +$305K ﹤0.01% 2021
2021
Q3 		$259K Buy
+26,034
New +$642K ﹤0.01% 2512

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

HRT Financial's SPRY Position: Q1 2026 in Review

HRT Financial sold out of ARS Pharmaceuticals (SPRY) in Q1 2026, closing a stake of 68,645 shares — an estimated $799K sold.

HRT Financial first reported a position in SPRY in Q3 2021 and held it in 5 quarters. The position peaked at $883K in Q1 2023. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • HRT Financial reported no remaining ARS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 68,645 ARS Pharmaceuticals shares in Q1 2026, an estimated $799K.
  • HRT Financial first reported a position in ARS Pharmaceuticals in Q3 2021 and held it in 5 quarters.
  • HRT Financial's ARS Pharmaceuticals position peaked at $883K in Q1 2023.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.